These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38402256)

  • 1. Inter-epitope spacer variation within polytopic L2-based human papillomavirus antigens affects immunogenicity.
    Zhang Y; Mariz FC; Sehr P; Spagnoli G; Koenig KM; Çelikyürekli S; Kreuziger T; Zhao X; Bolchi A; Ottonello S; Müller M
    NPJ Vaccines; 2024 Feb; 9(1):44. PubMed ID: 38402256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
    Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
    Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
    Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
    Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
    Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X
    Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus.
    Tumban E; Peabody J; Tyler M; Peabody DS; Chackerian B
    PLoS One; 2012; 7(11):e49751. PubMed ID: 23185426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types.
    Zhang T; Chen X; Liu H; Bao Q; Wang Z; Liao G; Xu X
    Vaccine; 2019 Jul; 37(30):4022-4030. PubMed ID: 31213378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
    Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
    PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles.
    Yang F; Mariz FC; Zhao X; Spagnoli G; Ottonello S; Müller M
    Front Immunol; 2020; 11():606569. PubMed ID: 33343580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
    Kalnin K; Chivukula S; Tibbitts T; Yan Y; Stegalkina S; Shen L; Cieszynski J; Costa V; Sabharwal R; Anderson SF; Christensen N; Jagu S; Roden RBS; Kleanthous H
    Vaccine; 2017 Sep; 35(37):4942-4951. PubMed ID: 28778613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
    Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
    PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
    Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
    Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
    Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
    Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
    J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.
    Wang D; Li Z; Xiao J; Wang J; Zhang L; Liu Y; Fan F; Xin L; Wei M; Kong Z; Yu H; Gu Y; Zhang J; Li S; Xia N
    PLoS One; 2015; 10(4):e0123944. PubMed ID: 25905781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.
    Bywaters SM; Brendle SA; Tossi KP; Biryukov J; Meyers C; Christensen ND
    Viruses; 2017 Nov; 9(11):. PubMed ID: 29125554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.
    Ahmels M; Mariz FC; Braspenning-Wesch I; Stephan S; Huber B; Schmidt G; Cao R; Müller M; Kirnbauer R; Rösl F; Hasche D
    Front Immunol; 2022; 13():1010790. PubMed ID: 36263027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.
    Wang JW; Wu WH; Huang TC; Wong M; Kwak K; Ozato K; Hung CF; Roden RBS
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29743371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.